$23M capped ALA partners with $1.1BN Imugene - Now Targeting 90% of Cancers

Yesterday, Arovella Therapeutics (ASX:ALA) announced that it had signed a partnership agreement with $1.1BN capped Imugene to develop its technology to target solid tumour cancer cells.

ASX Junior Has Early Success With K9 Cancer Trials: Human Trials Await

One ASX listed clinical stage oncology company is developing novel targeted cancer therapeutics for both humans and animals.

IMU Poised to Break into Oncolytic Virotherapy Space with Novel Cancer Therapy

The proposal for the exclusive license of patents covering the CF33 OV technology will be put to Imugene (ASX:IMU) shareholders for their approval at an Extraordinary Meeting of Shareholders to be held on 18 November.

GTG Signs Prestigious Collaboration Agreement for Fight Against Cancer

Emerging med-tech junior Genetic Technologies (ASX:GTG | NASDAQ:GENE) understands the importance of timely and precise targeting. Accessible predictive risk testing is where GTG lives and it has now signed a 3-year Collaboration Agreement with high profile US-based researcher Translational Genomics Research Institute (TGen).

One ASX Med-Tech is Set to Transform The $100+Billion Cancer Diagnostic Market

MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.

IMU’s Latest Cancer Treatment Acquisition Could Have Big Pharma Knocking

Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.

GTG Validates Cancer Tests As it Looks to Global Expansion

What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).

ASX Med-Tech’s Genetic Cancer Screening Enters China, Eyes Future Asian Growth

Genetic Technologies (ASX:GTG) is a provider of world-leading genetic risk assessment test products.

Could a Loxo Oncology Style Trial, Bring Loxo Style Results for PTX?

Clinical stage oncology company, Prescient Therapeutics (ASX:PTX) is in a fortunate position. It has two clinical candidates, four trials, and multiple possible pathways to market for its targeted therapies that address specific mutations that drive cancer and contribute to resistance.

ASX Biotech Eyes International Distribution of Overlooked Cancer Drug

Today’s biotech junior is in the business of repurposing late-stage drug assets that have been overlooked by big pharma.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.